Botox, Dysport, and Xeomin are three similar cosmetic products that are easy to confuse. But, what differentiates the three? What exactly do they have in common? And, what does this mean for you?
The Similarities
The Maker
Xeomin is manufactured by Merz Aesthetics. Dysport is produced by Galderma. Botox is the property of Allergan Co.
The Source
Botox, Dysport, and Xeomin are derived from botulinum toxin. The toxin is a protein that blocks neurotransmission, thus, causing flaccid paralysis.
The Differences
Compared to its competitors, Xeomin is purer and doesn’t have any additives. Thus, it’s less likely to cause adverse effects, and the body is less likely to become resistant to it.
While Dysport, by design, is primarily for medical procedures. The official Dysport website references spasticity and dystonia. Additionally, Dysport has aesthetic uses. But, its formula includes additives to dilute the product.
Lastly, the oldest of the three is Botox. The range of therapies and procedures for this product is quite vast, including spasticity, migraines, overactive bladder, spasms, dystonia, strabismus, hyperhidrosis, wrinkles, fine lines, and muscle stiffness. For a full list of side effects and uses of Botox, visit their official website.
What This Means For The Consumer
As a cosmetic client, you can ask your injector for more information. That includes asking for a full list of side effects, and cost-efficient alternatives. In this case, the benefits of variety in the menu at your disposal include pricing and results.
More Information
Do you want more information? If you have any questions about Botox, Dysport, or Xeomin, ask a doctor. They’ll be able to advise you according to your needs.
The information provided herein has been reviewed for accuracy, but cannot be guaranteed to be free of infallalacy. The information herein does not qualify as a diagnosis nor does it substitute a consultation with a licensed physician.
© 2018, 2020 ALLIED MEDICAL AND DIAGNOSTIC SERVICES LLC. ALL RIGHTS RESERVED.
PUBLISHED: 20181217
REVISED: 20200131